Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trichostatin A · 2 trials · 2 indications
Subjects will be asked about AEs weekly during the evaluation phase and at every follow-up visit; descriptions of AEs will include, at a minimum: date of onset, date ended, severity, seriousness, relationship to the study drug, and outcome.
Measured by spontaneous reporting of adverse events (AEs)
| Arm | Type | Description |
|---|---|---|
| Trichostatin A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Trichostatin A | DRUG | Topical Study Drug |
Inclusion Criteria: * Willingness to provide signed and dated written voluntary informed consent. * Adults with diagnosis of mild-to-severe DLSO/DSO affecting at least one great toenail. * Positive microscopic examination with KOH for dermatophyte hyphae. * Positive dermatophyte culture or mixed de...
Trichostatin A is an investigational small molecule being studied for onychomycosis of the toenail and for relapsed or refractory hematologic malignancies. It is in Phase 2 clinical development for onychomycosis and Phase 1 for hematologic malignancies.
Trichostatin A targets HDAC, or histone deacetylase. It is a small molecule being developed by Vanda Pharmaceuticals Inc. for potential use in dermatology and oncology indications.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is developing Trichostatin A. The company is conducting clinical trials of the drug for onychomycosis of the toenail and for relapsed or refractory hematologic malignancies.
Trichostatin A is in Phase 2 clinical development for onychomycosis of the toenail, based on an active Phase 2 trial. It is also being studied in a Phase 1 trial for relapsed or refractory hematologic malignancies.
Trichostatin A is being studied in NCT07065773, a Phase 2 trial for onychomycosis of the toenail with 50 participants in the United States. It is also in NCT03838926, a Phase 1 trial for relapsed or refractory hematologic malignancies with 42 participants in the United States and Poland.
Trichostatin A is not FDA approved. It is an investigational drug still in clinical development, with active trials in Phase 1 and Phase 2 for different indications.